IDH1 and acute myeloid leukemia: This might provide a rationale for the addition of PI in the AML treatment regime for identified patient subgroups with H3K27me3 loss and poor outcomes, i.e. intermediate and unfavorable AML, IDH1, ASXL1, SRSF2, U2AF1 and BCOR mutated patients.